Table 2 | Baseline ventilatory parameters.

Table 3 | Result of 6MWT before and after 7 days of ACT with Simeox.

1.58±0.75FEV1 (L)

Variable Value Value

62±29FEV1 %pred.

FVC (L) 2.80±1.92

83±22FVC %pred.

0.58±0.20FEV1/FVC

TLC (L) 5.14±1.30

92±18TLC %pred.

Unfortunately we were not able to repeat assessment of ventilatory parameters in all 13 patients after 7 days of ACT with Simeox.

In 6 patients who performed the second pulmonary function test measurements, FEV1 and FVC slightly increased by 60 mL and

180 mL respectively and Raw slightly decreased by 0.05 units after 7 days of therapy.

Results of 6 minute walking distance test (6MWT) before and after 7 days of ACT with Simeox available for 10 pts are presented

in the table 3.

Variable

Conclusions

Patients with non-CF bronchiectasis of different origin may benefit from the use of airway clearance technique during acute

exacerbation in hospital setting. Easy to use and efficient airway clearance technology may quickly and significantly improve quality of

life and exercise capacity of these patients. Simeox device was well tolerated by all studied patients and proved to be safe and easy

to handle even for older and disabled person.

At baseline 6MWT distance covered and desaturation (ΔSaO2) during exercise were 333.8±118.7 m and 4.82±7.15 % respectively.

Management of bronchiectasis exacerbation including ACT with Simeox resulted in significant prolongation by 74±117 m (23%) of

distance covered and reduction of oxygen desaturation during exercise by 0.9±1.2 % compared to baseline (p<0.05).

Selected ventilatory parameters at baseline are shown in the table 2.

Desaturation during exercise,

ΔSaO2 (%)

4.82±7.15At admission

4.40±7.60after 7 days

<0.05p value

Distance (m)

333.8±118.7

411.6±87.1

0.036

0.42±1.00

0.00±0.00

1.17±1.95

1.10±2.28

at rest the end of walk

Dyspnea (Borg scale)

2.39±1.20RV (L)

RV %pred. 108±49

0.54±0.21Raw (kPa/L/sec)

181±69Raw %pred.

sGaw (1/kPa*sec) 0.61±0.30

65±31sGaw %pred.

31